What are Merck's latest KEYTRUDA collaborations?

Merck announced two new collaborations: one with Erasca to test ERAS-0015 in solid tumors, and another with Inhibrx where Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer showed positive results.

Why is Merck expanding KEYTRUDA partnerships now?

Because KEYTRUDA's patents are nearing expiry, which could lead to revenue decline. The partnerships aim to develop new combination therapies to extend the drug's commercial life.

ERAS-0015 is an experimental compound from Erasca being tested in combination with KEYTRUDA in RAS-mutant solid tumors.

What were the Phase 2 results for INBRX-106?

Interim data showed encouraging responses in head and neck cancer patients, and the companies plan to move to Phase 3.

Merck Broadens KEYTRUDA Collaborations as Patent Expiry Looms

Merck (NYSE:MRK) is expanding its KEYTRUDA clinical collaborations through a new partnership with Erasca to test ERAS-0015 in RAS-mutant solid tumors, and positive Phase 2 data with Inhibrx in head and neck cancer, strengthening its oncology pipeline ahead of key patent expiries.

Merck (NYSE:MRK) announced an expansion of its clinical collaborations around KEYTRUDA (pembrolizumab) through two new partnerships, as the company faces increasing pressure from upcoming patent expirations on its blockbuster drug.

Details of the New Collaborations

Collaboration with Erasca

Merck entered into a collaboration agreement with Erasca to test the compound ERAS-0015 in combination with KEYTRUDA for the treatment of RAS-mutant solid tumors. The partnership aims to explore the efficacy of this combination in patients who have not responded to existing therapies.

Collaboration with Inhibrx

Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 (an OX40 agonist) combined with KEYTRUDA in patients with head and neck cancer. The data showed encouraging responses, and the companies plan to advance to Phase 3 trials.

Strategic Context

These partnerships come at a time when Merck is facing increasing pressure as KEYTRUDA's patent protection nears expiration. KEYTRUDA is one of Merck's most important revenue sources. By expanding external collaborations, the company aims to strengthen its oncology pipeline and develop new combination therapies that could extend the drug's commercial life.

What This Means for Investors

These moves reflect Merck's focus on innovation through external partnerships to offset the expected revenue decline after patent expiration. For investors, the success of these clinical trials could provide a boost to the pipeline and mitigate the risks of loss of exclusivity.